Director
Office of Blood Research and Review (OBRR), CBER, FDA
Silver Spring, Maryland
Disclosure information not submitted.
AM25-MN-40-L - COVID-19 Convalescent Plasma in the Immunocompromised Patient
Monday, October 27, 2025
3:45 PM - 4:45 PM PT
AM25-TU-13-L - 2025 Ask the FDA and CMS/CLIA
Tuesday, October 28, 2025
9:30 AM - 11:00 AM PT